Filing Flows › Verrica Pharmaceuticals (VRCA) › Q3 2025
Verrica Pharmaceuticals (VRCA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Verrica Pharmaceuticals (VRCA) reported revenue of $14.3M for the third quarter 2025 (Q3 2025) and +13% from the quarter before. Operating margin was 11.3%, net loss $274K (1.9% of revenue).
Verrica Pharmaceuticals, Q3 2025: revenue $14.3M, operating margin 11.3%, net loss $274K, operating cash flow $9.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.3M | +13% | — |
| Operating profit | $1.6M | +8% | — |
| Net earnings | −$274K | -234% | — |
| Operating cash flow | $9.7M | — | — |
What changed
Revenue was $14.3M in Q3 2025, up 13% from the previous quarter. License and collaboration revenue was the largest line at 75% of revenue.
Operating profit was $1.6M, a 11.3% margin. The quarter ended with a net loss of $274K, after a profit of $204K the previous quarter. Net interest and other expense of $1.9M was the main reason.
Operating cash flow was $9.7M. Non-cash charges added back $22K of depreciation and $718K of share-based compensation. Working capital and other items added $9.2M.
Questions
What was Verrica Pharmaceuticals' revenue in the third quarter 2025?
Verrica Pharmaceuticals (VRCA) reported revenue of $14.3M for the third quarter 2025 (Q3 2025) and +13% from the quarter before.
Was Verrica Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $1.6M (11.3% of revenue) and net loss $274K.